Quick leadership change at Cal eConnect

The Cal eConnect board of directors announced that Ted Kremer has decided to withdraw as CEO and remain at the helm of a local regional health information organization in Rochester, N.Y.  This announcement comes only two weeks after the board announced Kremer's appointment.

Laura Landry, who has been acting as interim CEO, will assume the top post.

“While we are disappointed with Ted’s decision, we want to assure the California healthcare community that Cal eConnect is continuing to move forward with its strategy for connecting California,” said Don Crane, Cal eConnect Board co-chair and president and CEO of the California Association of Physician Groups. “We have a strong staff and a highly supportive relationship with the state, as well as funding from a federal grant to California for health information exchange (HIE). Our strategy has been developed in collaboration with hundreds of people around the state who are invested in the success of HIE in California and was recently recognized by the head of the federal health IT program as being in alignment with national strategy. We look forward to making rapid progress over the coming months.”
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.